REGENXBIO Inc. (RGNX)
NASDAQ: RGNX · Real-Time Price · USD
8.55
-0.30 (-3.39%)
Feb 11, 2026, 3:56 PM EST - Market open
REGENXBIO Employees
REGENXBIO had 353 employees as of December 31, 2024. The number of employees increased by 9 or 2.62% compared to the previous year.
Employees
353
Change (1Y)
9
Growth (1Y)
2.62%
Revenue / Employee
$456,992
Profits / Employee
-$504,008
Market Cap
432.83M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2024 | 353 | 9 | 2.62% | 353 | 0 |
| Dec 31, 2023 | 344 | -57 | -14.21% | 344 | 0 |
| Dec 31, 2022 | 401 | 29 | 7.80% | 401 | 0 |
| Dec 31, 2021 | 372 | 66 | 21.57% | 372 | 0 |
| Dec 31, 2020 | 306 | 49 | 19.07% | 306 | 0 |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Jun 30, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Vanda Pharmaceuticals | 368 |
| Niagen Bioscience | 104 |
| Invivyd | 100 |
| Lineage Cell Therapeutics | 77 |
| Assembly Biosciences | 73 |
| PureTech Health | 56 |
| Eupraxia Pharmaceuticals | 33 |
| DiaMedica Therapeutics | 28 |
RGNX News
- 1 day ago - FDA Rejection Clouds Path For REGENXBIO's Rare Disease Treatment - Benzinga
- 1 day ago - US FDA declines to approve Regenxbio's rare disease drug - Reuters
- 1 day ago - REGENXBIO Announces Regulatory Update on RGX-121 BLA for MPS II - PRNewsWire
- 8 days ago - RGNX Investors Have Opportunity to Join REGENXBIO Inc. Fraud Investigation with the Schall Law Firm - Business Wire
- 12 days ago - Investigation into Regenxbio: Questions Arise Over Disclosure Completeness Prior to FDA Action - PRNewsWire
- 14 days ago - FDA Clinical Hold Knocks REGENXBIO Stock - Benzinga
- 14 days ago - US FDA places clinical hold on Regenxbio's gene therapy trials - Reuters
- 14 days ago - REGENXBIO Announces Regulatory Update on Ultra Rare MPS Programs - PRNewsWire